|
1
|
Le Blanc K, Frassoni F, Ball L, Locatelli
F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger
M, et al: Mesenchymal stem cells for treatment of
steroid-resistant, severe, acute graft-versus-host disease: A phase
II study. Lancet. 371:1579–1586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kharaziha P, Hellström PM, Noorinayer B,
Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost
M, Zali MR and Soleimani M: Improvement of liver function in liver
cirrhosis patients after autologous mesenchymal stem cell
injection: A phase-II clinical trials. Eur J Gastroenterol Hepatol.
21:1199–1205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vojtassák J, Danisovic L, Kubes M, Bakos
D, Jarábek L, Ulicná M and Blasko M: Autologous biograft and
mesenchymal stem cells in treatment of the diabetic foot. Neuro
Endocrinol Lett. 27(Suppl 2): S134–S137. 2006.
|
|
4
|
Guiducci S, Porta F, Saccardi R, Guidi S,
Ibba-Manneschi L, Manetti M, Mazzanti B, Dal Pozzo S, Milia AF,
Bellando-Randone S, et al: Autologus mesenchymal stem cells foster
revascularization of ischemic limbs in systemic sclerosis: A case
report. Ann Intern Med. 153:650–654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Phinney DG and Prockop DJ: Concise review:
Mesenchymal stem/multipotent stromal cells: The state of
transdifferentiation and modes of tissue repair-current views. Stem
Cells. 25:2896–2902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bordignon C, Carlo-Stella C, Colombo MP,
De Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A,
Rondelli D, Zanon P and Tura S: Cell therapy: Achievements and
perspectives. Haematologica. 84:1110–1149. 2011.
|
|
7
|
Bassi EJ, Aita CA and Câmara NO: Immune
regulatory properties of multipotent mesenchymal stromal cells:
Where do we stand? World J Stem Cells. 3:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi M, Liu ZW and Wang FS:
Immunomodulatory properties and therapeutic application of
mesenchymal stem cells. Clin Exp Immunol. 164:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han KH, Ro H, Hong JH, Lee EM, Cho B, Yeom
HJ, Kim MG, Oh KH, Ahn C and Yang J: Immunosuppressive mechanisms
of embryonic stem cells and mesenchymal stem cells in alloimmune
response. Transpl Immunol. 25:7–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y and Lin F: Mesenchymal stem cells are
injured by complement after their contact with serum. Blood.
120:3436–3443. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allison M: Genzyme backs Osiris, despite
prochymal flop. Nat Biotechnol. 27:966–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spaggiari GM, Capobianco A, Becchetti S,
Mingari MC and Moretta L: Mesenchymal stem cell-natural killer cell
interactions: Evidence that activated NK cells are capable of
killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell
proliferation. Blood. 107:1484–1490. 2006. View Article : Google Scholar
|
|
13
|
Akira S, Uematsu S and Takeuchi O:
Pathogen recognition and innate immunity. Cell. 124:783–801. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blasius AL and Beutler B: Intracellular
toll-like receptors. Immunity. 32:305–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Opitz CA, Litzenburger UM, Lutz C, Lanz
TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher
WK, et al: Toll-like receptor engagement enhances the
immunosuppressive properties of human bone marrow-derived
mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1
via interferon-beta and protein kinase R. Stem Cell. 27:909–919.
2009. View
Article : Google Scholar
|
|
16
|
Pevsner-Fischer M, Morad V, Cohen-Sfady M,
Rousso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR and Zipori D:
Toll-like receptors and their ligands control mesenchymal stem cell
function. Blood. 109:1422–1432. 2007. View Article : Google Scholar
|
|
17
|
DelaRosa O and Lombardo E: Modulation of
adult mesenchymal stem cells activity by toll-like receptors:
Implications on therapeutic potential. Mediators Inflamm.
2010:8656012010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Liu D, Pu D, Wang Y, Li L, He Y,
Li Y, Li L and Li W: The TLR7 agonist imiquimod promote the
immunogenicity of msenchymal stem cells. Biol Res. 48:62015.
View Article : Google Scholar :
|
|
19
|
Zhang L, Liu D, Pu D, Wang Y, Li L, He Y,
Li Y, Li L, Qiu Z, Zhao S and Li W: The role of toll-like receptor
3 and 4 in regulating the function of mesenchymal stem cells
isolated from umbilical cord. Int J Mol Med. 35:1003–1010.
2015.PubMed/NCBI
|
|
20
|
Arocho A, Chen B, Ladanyi M and Pan Q:
Validation of the 2-DeltaDeltaCt calculation as an alternate method
of data analysis for quantitative PCR of BCR-ABL P210 transcripts.
Diag Mol Path. 15:56–61. 2006. View Article : Google Scholar
|
|
21
|
Huang XP, Sun Z, Miyagi Y, McDonald
Kinkaid H, Zhang L, Weisel RD and Li RK: Differentiation of
allogeneic mesenchymal stem cells induces immunogenicity and limits
their long-term benefits for myocardial repair. Circulation.
122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pittenger MF, Mackay AM, Beck SC, Jaiswal
RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and
Marshak DR: Multilineage potential of adult human mesenchymal stem
cells. Science. 284:143–147. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Augello A, Kurth TB and De Bari C:
Mesenchymal stem cells: A perspective from in vitro cultures to in
vivo migration and niches. Eur Cell Mater. 20:121–133. 2010.
|
|
24
|
Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee
IH, Lin WS, Wu CH, Lin WY and Cheng SM: Mesenchymal stem cells from
human umbilical cord express preferentially secreted factors
related to neuroprotection, neurogenesis, and angiogenesis. PLoS
One. 8:e726042013. View Article : Google Scholar : PubMed/NCBI
|
